Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of cholecalciferol (Vitamin D3) and metformin, being investigated for the treatment of infertility in women with polycystic ovary syndrome (PCOS) and Vitamin D deficiency. Metformin is a biguanide that improves insulin sensitivity and reduces hyperandrogenism, which are central to PCOS pathophysiology. Cholecalciferol is a seco-steroid that, upon conversion to its active form, binds to the Vitamin D receptor (VDR) to influence various metabolic and reproductive processes. The combination is hypothesized to provide superior outcomes in follicular development and hormonal balance compared to metformin alone. The Aga Khan University sponsored a randomized open-label trial to evaluate these effects, specifically looking at follicle size, endometrial thickness, and androgen levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholecalciferol + metformin.